Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Atomic-resolution structure of a chimeric Powassan tick-borne flavivirus
Das, Sayan , Narayanan, Anoop , Wang, Anqi , Moustafa, Ibrahim M. , Cho, Sung Hyun , Mitzel, Dana , Jose, Joyce , Hafenstein, Susan , Hafenstein, Susan L

Science Advances | July 9, 2025 | Volume: 11 | Issue: 28 | Pages: No page available

10.1126/sciadv.adw7700 | PMID 40632869 Get It

Powassan virus (POWV) is an emerging tick-borne flavivirus for which no vaccine or antiviral treatment exists. The incidence of human infections of POWV in North America has been increasing because of the expanding distribution of the tick vector Ixodes scapularis that transmits POWV to humans. To mitigate the dangers of handling a risk group 3 human pathogen, a chimeric virus was constructed from the genetic backbone of a yellow fever virus vaccine strain 17D (YFV-17D) and the external structural proteins of POWV lineage II. The chimera had a comparable phenotype as POWV. The atomic resolution of yellow fever virus-Powassan virus chimera (yPOWV) structure was built without ambiguity, revealing surface glycans and lipid pocket factors. The similarity to other flavivirus structures and the phenotype similar to YFV-17D suggest that there could be future potential as a vaccine candidate.
The Challenges of Nocardia Susceptibility Testing and Interspecies Susceptibility Patterns
Wengenack, Nancy L. , Beam, Elena , Wengenack, Nancy L , Beam, Elena , Yetmar, Zachary A.

Clinical Infectious Diseases | July 9, 2025 | Volume: 81 | Issue: 6 | Pages: e735-e736

10.1093/cid/ciaf374 | PMID 40632806 Get It

Salivary microbiome and serum metabolomics add to clinical biomarkers to predict 6-month hospitalizations in a multicenter cirrhosis outpatient cohort
Bajaj, Jasmohan S. , Reddy, K. Rajender , O’Leary, Jacqueline G. , García–Tsao, Guadalupe , Vargas, Hugo E. , Kamath, Patrick S. , Biggins, Scott W. , Vutien, Phillip, Shaw, Jawaid , Miro, Ana Teresa Limon, Bera, Chinmay , McGinley, Joseph , Sikaroodi, Masoumeh , Bush, Brian J., Gillevet, Patrick M. , Vargas, Hugo E , Bera, Chinmay , Tandon, Puneeta , Lai, Jennifer C. , Wong, Florence , Miro, Ana Teresa Limon, BUSH, BRIAN J. , Thacker, Leroy R.

Hepatology | July 9, 2025 | Volume: 83 | Issue: 6 | Pages: 1483-1494

10.1097/hep.0000000000001462 | PMID 40632657 Get It

Background and Aims: Prognosticating outcomes such as hospitalizations in outpatients with cirrhosis is challenging, especially with changing etiologies and demographics. This study aims to determine the impact of multi-omic strategies on outcome prediction. Approach and Results: NACSELD3 enrolls outpatients with cirrhosis with controlled/eradicated etiologies from 10 centers and follows them systematically. At baseline, clinical/demographic and cirrhosis details were recorded and saliva and serum samples were collected for microbiome and metabolome analysis, respectively. Multi-omic bioinformatic studies to determine the interaction of microbiota and metabolites with the clinical prediction of 6-month hospitalizations were performed. Five hundred sixty-five patients (60.2 y, 68% men, 35% alcohol, 33% metabolic dysfunction-associated steatohepatitis, 21%, eradicated HCV with MELD 3.0 12) were enrolled. One hundred sixty-three (29%) required 6-month hospitalizations; most (75%) were liver-related. Those hospitalized had worse cirrhosis severity and comorbidity indices but similar demographics and oral health variables. Salivary microbiome alpha-diversity was lower (1.96±0.48 vs. 2.09±0.45, p =0.018) with greater pathobionts ( Streptococcus , Treponema, Enterococcaceae) and lower commensal genhospitalized/noera ( Veillonella, Prevotella, Haemophilus , Lachnospiraceae spp) at baseline. Serum metabolomics showed significant separation at baseline between hospitalized/non-hospitalized patients using supervised analyses with microbial-origin (phenyllactate, secondary bile acids, indoles), choline moieties, and polyamine/GABA (3-ureidopropionate/spermidine) metabolites being most prominent. Area under the curve using random forest for clinical, microbial, and metabolomic variables was higher than that of these individually. Latent factor analysis showed clinical variables (MELD 3.0, hemoglobin, and albumin) with the greatest impact, followed by salivary microbiota and then serum microbiome for hospitalization prediction. Conclusions: In a multicenter North American outpatient cirrhosis cohort with controlled etiologies, serum metabolomics and salivary microbiome add to clinical variables to prognosticate 6-month hospitalization.
Mission Impossible: Endoscopic Restoration of Gastrointestinal Lumen Continuity
Chopra, Preeyati , Buttar, Davekaran, Bhatt, Mahin C., Ohri, Ashwariya , Buttar, Navtej , Goyal, Mayank, Bhatt, Mahin C., Dayyeh, Barham K. Abu , Vargas, Eric J.

ACG Case Reports Journal | July 9, 2025 | Volume: 12 | Issue: 7 | Pages: e01763

10.14309/crj.0000000000001763 Get It

ABSTRACT Anastomotic leaks following complex gastrointestinal surgeries pose a significant challenge, especially in patients unfit for further surgical intervention. We present a novel 3-staged endoscopic approach to restore gut continuity in a 55-year-old woman with multiple anastomotic leaks and discontinuous bowel segments following extensive abdominal surgeries. The procedure included stent placement, endoscopic ultrasound (EUS)-guided gastrojejunostomy with a lumen-apposing metal stent (LAMS), and fistula plug insertion with glue. Over 6 months, bowel continuity was restored, and at 6-year follow-up, the patient remains symptom free, tolerating oral intake. This case demonstrates the transformative potential of advanced endoscopic techniques in managing complex gastrointestinal disruptions without further surgery.
Facial Anatomy Teaching for Aesthetic Surgery: Using 3-dimensional Photogrammetry and Immersive Virtual Reality
Hussein, Sara , Emanuels, Andrew F., Leonel, Luciano, Lachman, Nirusha , Celda, María Peris, Sheahan, Eric M., Martinez, Erick O., Leonel, Luciano César P C, Peris Celda, Maria, Hanson, Christian R., Emanuels, Andrew, Morris, Jonathan M. , Martinez, Erick O., Hanson, Christian R., Sharaf, Basel

Plastic and Reconstructive Surgery - Global Open | July 9, 2025 | Volume: 13 | Issue: 7 | Pages: e6972

10.1097/gox.0000000000006972 | PMID 40642258 Get It

Summary: Anatomy is a critical component of surgical training; however, traditional resources—such as Netter’s Surgical Anatomy , Gray’s Anatomy , and anatomy applications—often fall short in delivering surgically relevant, 3-dimensional (3D) perspectives of facial anatomy. Although cadaveric dissection remains a valuable teaching tool, its accessibility is limited by cost, ethical concerns, and the lack of structured curricula, making it less feasible for ongoing surgical education. To address these limitations, this article introduced a novel educational approach that integrates 3D photogrammetry and virtual reality technology into the surgical anatomy curriculum for craniofacial and aesthetic surgery. Six fresh cadaveric specimens were meticulously dissected by a plastic surgeon to illustrate the intricate layered anatomy of the face and neck. At each stage of the dissection, a photogrammetry technique was used to capture 360-degree images using 5 digital single-lens reflex cameras alongside a 3D handheld camera. This approach not only ensured high-quality imaging but also facilitated the creation of detailed, lifelike virtual 3D models, enhancing the understanding of facial and neck anatomy within a surgical context. Additionally, we present some technical refinements of the 3D volume renderings to capture precise anatomical details during our dissections. Preliminary results from the use of this technology in anatomy courses and workshops indicated trainee engagement, a clearer grasp of the spatial anatomical relationships, and greater confidence in applying this knowledge to hands-on surgical procedures.
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Razzo, Beatrice M. , Midha, Shonali , Portuguese, Andrew J. , Grajales‐Cruz, Ariel , Corraes, Andre De Menezes Silva , Costello, Patrick , Liu, Yuxin , Sperling, Adam S. , Nadeem, Omar , Dima, Danai , Cowan, Andrew J. , Afrough, Aimaz , Anderson, Larry D. , Goyal, Anmol , Ferreri, Christopher J. , Voorhees, Peter M. , Patel, Krina K. , Julian, Kelley , Forsberg, Peter A. , Susanibar-Adaniya, Sandra P. , Khouri, Jack , Raza, Shahzad , Vazquez‐Martinez, Mariola , Sborov, Douglas W. , Davis, James A. , Shune, Leyla , Bhurtel, Jenny , Hwang, Wei‐Ting , Sidana, Surbhi , Grajales-Cruz, Ariel F , De Menezes Silva Corraes, Andre , Banerjee, Rahul , Cowan, Andrew J , Afrough, Aimaz , Anderson, Larry D , Lieberman-Cribbin, Alex , Kaur, Gurbakhash , Goyal, Anmol , Atrash, Shebli , Ferreri, Christopher , Voorhees, Peter , Pasvolsky, Oren , Lee, Hans C , Patel, Krina , Julian, Kelley L , Forsberg, Peter A , Herr, Megan M. , Chhabra, Saurabh , Parrondo, Ricardo D , Lin, Yi , Chen, Anna , Susanibar-Adaniya, Sandra P , Khouri, Jack , Raza, Shahzad , Anwer, Faiz , Vazquez-Martinez, Mariola A , Castaneda Puglianini, Omar , Sborov, Douglas W , Davis, James A , Rossi, Adriana , Shune, Leyla , Bhurtel, Evguenia , Hwang, Wei-Ting , Hansen, Doris K , Sidana, Surbhi , Garfall, Alfred L , Richard, Shambavi , Nadeem, Omar , Dima, Danai , Sperling, Adam S , Portuguese, Andrew J , Banerjee, Rahul , Kaur, Gurbakhash , Atrash, Shebli , Pasvolsky, Oren , Lee, Hans C. , Chhabra, Saurabh , Lin, Yi , Anwer, Faiz , Puglianini, Omar Castañeda , Rossi, Adriana , Hansen, Doris K. , Garfall, Alfred L. , Richard, Shambavi

Blood Cancer Discovery | July 9, 2025 | Volume: 6 | Issue: 6 | Pages: 561-571

10.1158/2643-3230.bcd-24-0354 | PMID 40629516 Get It

Abstract Teclistamab is an anti-CD3-/B-cell maturation antigen (BCMA) bispecific antibody approved for use in relapsed/refractory multiple myeloma. We undertook a retrospective study of post-approval, real-world outcomes with teclistamab in the US Multiple Myeloma Immunotherapy Consortium. Among 509 patients, 89% would have been ineligible for the MajesTEC-1 trial, primarily due to prior BCMA-directed therapy, cytopenias, or diminished performance status. Cytokine release syndrome occurred in 54% (1.4% grade ≥3) and immune effector cell–associated neurotoxicity syndrome in 11% (2.2% grade ≥3), with no fatal events. Infections occurred in 42% and contributed to death in 5%. Partial response (PR) or better was achieved in 53% and very good PR or better in 45%. With 10.1 months of median follow-up, the estimated median progression-free survival (PFS) was 5.8 months and 12-month overall survival was 61%. Independent predictors of less than very good PR and shorter PFS included BCMA-directed chimeric antigen receptor T-cell therapy in the previous 9 months, high disease burden, lymphopenia, and elevated ferritin. Significance: T cell–engaging bispecific antibodies such as teclistamab represent an important new treatment modality for multiple myeloma and other blood cancers. This study evaluates the real-world safety and efficacy of teclistamab, including its activity in populations not represented in the initial phase I/II study, and identifies clinical variables associated with treatment response. See related commentary by Zweegman et al., p. 542
Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-bl
Bobek, Olivia , Fenske, Timothy S. , Stiff, Patrick J. , Hill, Brian T. , Geyer, Susan M. , Horwitz, Mitchell E. , Little, Richard F. , Dinner, Shira, Friedberg, Jonathan W. , Perales, Miguel-Angel, Leonard, John P. , Bobek, Olivia , Andreadis, Charalambos Babis , Hsi, Eric D. , Khimani, Farhad , Kahl, Brad S. , Devine, Steven M. , Bartlett, Nancy L.

Leukemia & Lymphoma | July 9, 2025 | Volume: 66 | Issue: 10 | Pages: 1903-1912

10.1080/10428194.2025.2525982 | PMID 40632607 Get It

Disorders of Consciousness Are Not Necessarily Disorders of Permanence: Reconsidering Risk-Making in a Dynamic Spectrum
Milian, Ricardo Diaz , Rabai, Ferenc , Diaz Milian, Ricardo

AJOB Neuroscience | July 9, 2025 | Volume: 16 | Issue: 3 | Pages: 153-155

10.1080/21507740.2025.2519435 | PMID 40632131 Get It

Development of a Hepatocyte‐Specific Temporal Genetic Mouse Model Using Albumin Promoter‐Driven FlpER2 Expression
Wang, Bin , Wang, Jiale , Liu, Yang , He, Gordon, Jahan‐mihan, Yasmin , Hu, Jie , Li, Audrey , Bi, Yan , Ji, Baoan , Wang, Yuxi, Muhammad, Faheem, Wang, Jiale , Wang, Bin , He, Gordon, Wang, Di , Faheem, Muhammad

genesis | July 9, 2025 | Volume: 63 | Issue: 4 | Pages: No page available

10.1002/dvg.70022 | PMID 40631533 Get It

ABSTRACTTissue‐specific gene manipulation using Cre/loxP or Flp/frt recombination systems is a cornerstone of genetically engineered mouse models. In this study, we aim to develop a novel hepatocyte‐specific, tamoxifen‐inducible Flp mouse line. BAC (bacterial artificial chromosome)‐Alb(albumin)‐FlpER2(estrogen receptor ligan binding domain) was developed by inserting IRES‐FlpER2 cDNA between the translation stop codon and 3′‐UTR of the mouse albumin gene in a bacterial artificial chromosome. Upon tamoxifen induction in mice crossed with reporter lines, western blotting, immunohistochemistry, immunofluorescence staining, and X‐gal staining (5‐bromo‐4‐chloro‐3‐indolyl‐β‐D‐galactopyranoside Staining) were used to verify the recombination efficiency and specificity of this mouse model. Recombination was highly efficient and specific in hepatocytes, with no recombination detected in intrahepatic cholangiocytes or other organs in this mouse model. We generated a new tamoxifen‐induced hepatocyte‐specific mouse model with highly efficient recombination specifically in hepatocytes, and this model can be used to generate tumor model lines.
Discrepancies between CSF biomarker and PET determinations of elevated brain amyloid and their prognostic significance
Weigand, Stephen D. , Wiste, Heather J. , Graff‐Radford, Jonathan, Graff‐Radford, Neill R., Petersen, Ronald C., Jack, Clifford R. , Lowe, Val J. , Fields, Julie A. , Neth, Bryan J. , Day, Gregory S. , Kantarci, Kejal, Bornhorst, Joshua A. , Initiative, and the Alzheimer's Disease Neuroimaging, Kantarci, Kejal , Neth, Byran J. , Jack, Clifford R , Kantarci, Kejal , Day, Gregory S , Bornhorst, Joshua , Knopman, David S. , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Petersen, Ronald C. , Boeve, Bradley F. , Machulda, Mary M. , Ramanan, Vijay K. , Botha, Hugo , McCarter, Stuart J. , Jones, David T. , Algeciras‐Schimnich, Alicia , Johnson, Derek R. , Initiative, and the Alzheimer's Disease Neuroimaging

Alzheimer's & Dementia | July 9, 2025 | Volume: 21 | Issue: 7 | Pages: No page available

10.1002/alz.70468 | PMID 40631430 Get It

Abstract INTRODUCTION When cerebrospinal fluid (CSF) and positron emission tomography (PET) measurements for amyloid‐beta‐peptide (Aβ) related pathology are discordant, therapeutic decision‐making becomes uncertain. METHODS Using data from patients with mild cognitive impairment ( n = 541) from the Alzheimer's Disease Neuroimaging Initiative, we examined baseline characteristics and longitudinal clinical outcomes in persons grouped according to normal/abnormal Aβ via concurrent CSF and PET determinations using standard cutpoints. RESULTS Discordant groups for brain Aβ status (CSF+/PET− and CSF−/PET+) each represented about 5% of the mild cognitive impairment (MCI) population. Longitudinally, neither discordant group declined more than the CSF−/PET− group on either a memory measure or the Clinical Dementia Rating Sum of Boxes scores over a median 4 years of observation, while the CSF+/PET+ group exhibited worsening on both measures. DISCUSSION In contrast to the clinical decline observed in the CSF+/PET+ group, persons with MCI and CSF+/PET− or CSF−/PET+ brain amyloid patterns did not exhibit incipient decline. Highlights Discrepant abnormal cerebrospinal fluid (CSF) and positron emission tomography (PET) brain amyloid indicators are uncommon in mild cognitive impairment (MCI). CSF‐PET discrepant persons with MCI tend to have less abnormal values initially. CSF‐PET discrepant persons with MCI have a benign prognosis at 4 years.